Teva Sweden AB Box Helsingborg

Transcription

1 6 th Nordic MS Symposium Stockholm January 2018

2 Teva Sweden AB Box Helsingborg SW/MEETING/17/0002 Okt-2017

3 6 th Nordic MS Symposium Gender Aspects and Comorbidities in Multiple Sclerosis Scandic Continental Vasagatan Stockholm Sweden January 2018 Invitation Co-sponsor

4 Invitation Teva is happy to announce next year s Teva Nordic MS Symposium, which will be held in Stockholm, Sweden January The topics and speakers have been selected by a Steering Committee consisting of a leading MS expert from each Nordic country. The Steering Committee consists of: Jan Lycke Professor of Neurology, Sahlgrenska University Hospital, Sweden Hanna Kuusisto Head of Neurology at Kanta-Häme, Docent of Neurology at Tampere University, Finland Elisabeth Gulowsen Celius Professor and Head of Department of Neurology, Oslo University Hospital, Ullevål, Norway Finn Sellebjerg Professor of Neurology, Rigshospitalet, University of Copenhagen, Denmark Registration Send an to Fredrik Blomstrand, fredrik.blomstrand@teva.se stating that you would like to participate in this meeting. Please state your name, address and contact info. Or, use the attached registration card. Deadline for registration is 8 January Contact If you have any questions regarding the symposium, please contact Fredrik Blomstrand, Teva Sweden. fredrik.blomstrand@teva.se. Phone: +46 (0) We look forward to seeing you in Stockholm. The Steering Committee and Teva Neuroscience About the Nordic MS symposium TEVA is a global company working in generics and specialty medicine. In MS, TEVA has a long tradition, and is committed to bringing medicine, education and innovative solutions to health care professionals and with the ultimate goal of improving patient lives. Aligned with this commitment, TEVA Nordics has since 2013 arranged an annual scientific symposium intended to be complementary to other international congresses and with highest clinical and scientific relevance. The symposium has been attended by top international MS experts and provided young Nordic neurologists and researchers an opportunity to present their work in an environment facilitating interactions and discussions. Reports from previous meetings can be downloaded from and under Utbildningar.

5 Day 1 Programme Gender aspects 12:00-13:00 Arrival, registration and lunch Session 1 Epidemiology & Genetics Moderator: Jan Lycke, Gothenburg, Sweden 13:00-13:10 Welcome and opening Fredrik Blomstrand, TEVA Sweden 13:10-13:55 Epidemiology and changes over time Kjell-Morten Myhr, Bergen, Norway 13:55-14:40 Genes, lifestyle factors and their interaction in MS Tomas Olsson, Stockholm, Sweden 14:40-15:00 Coffee break Session 2 Sex hormones and MS Moderator: Hanna Kuusisto, Tampere, Finland 15:00-15:45 Impact of sex hormones on the immune system Laura Airas, Turku, Finland 15:45-16:15 Clinical impact of sex hormone treatment Elisabeth Gulowsen Celius, Oslo, Norway 16:15-16:30 Coffee break Session 3 Management of DMT Moderator: Elisabeth Gulowsen Celius, Oslo, Norway 16:30-17:15 Gender and treatment response Melinda Magyari, Copenhagen, Denmark 17:15-18:00 Pregnancy & breast feeding Kerstin Hellwig, Bochum, Germany 18:00 Wrap up Day 1

6 Programme Comorbidities Day 2 Session 4 Comorbidities in MS Moderator: Finn Sellebjerg, Copenhagen, Denmark 08:30-09:15 Evaluating the influence from comorbidities on MS and their socioeconomic consequences. Anja Thormann, Copenhagen, Denmark 09:15-10:00 Comorbid diseases: risks for MS, other autoimmune diseases, incidental findings and consequences Scott Montgomery, Örebro, Sweden 10:00-10:40 Bone Health and bone mineral density Stine Marit Moen, Oslo, Norway 10:40-11:00 Coffee break, check out 11:00-11:30 Psychiatric co-morbidity Päivi Hämäläinen, Masku, Finland 11:30-12:00 Comorbidities and limits for DMTs Jan Lycke, Gothenburg, Sweden Wrap up day 2 and symposium 12:30 Standing lunch and departures The programme shown may be subject to change. This invitation and meeting is to Teva Sweden s knowledge in compliance with the LIF/SKL agreement for interactions.